Premium
Impaired glucose tolerance in first‐episode drug‐naïve patients with schizophrenia
Author(s) -
Spelman L. M.,
Walsh P. I.,
Sharifi N.,
Collins P.,
Thakore J. H.
Publication year - 2007
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/j.1464-5491.2007.02092.x
Subject(s) - medicine , impaired glucose tolerance , schizophrenia (object oriented programming) , diabetes mellitus , genetic predisposition , type 2 diabetes mellitus , psychosis , psychiatry , type 2 diabetes , endocrinology , disease
Abstract Aims To determine whether there is an association between Type 2 diabetes mellitus and schizophrenia, independent of medication. Methods In this cross‐sectional study we performed an oral glucose tolerance test on 38 non‐obese white Caucasians who fulfilled the criteria for first‐episode drug‐naïve schizophrenia, 38 control subjects (matched for age, gender, smoking status, alcohol intake and ethnicity) and 44 first‐degree relatives of the patients. Results The frequency of impaired glucose tolerance (IGT), defined by World Health Organization criteria, was 10.5% ( n = 4) in patients with schizophrenia, 18.2% ( n = 8) in unaffected relatives and 0.0% in healthy control subjects (χ 2 = 4.22, d.f. = 2, P < 0.05). Conclusions The high point prevalence of IGT in never‐treated patients and relatives supports either shared environmental or genetic predisposition to IGT. Both patients and their relatives present an ideal cost‐effective opportunity to screen for Type 2 diabetes mellitus, as they are both easily identifiable.